Stockreport

TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF supplemental new drug application (sNDA) seeking label expansion for its marketed drug, Filspari (sparsentan), in the focal segmental glomerulosclerosis (FSGS) indicatio [Read more]